Patent · US Active

Cancer therapy with a parvovirus combined with an HDAC inhibitor

US9592260B2 · kind B2 · utility

2Cited by

0References

3Claims

0Family size

Assignee

Deutsches Krebsforschungszentrum · DE

Inventors

Antonio Marchini · Heidelberg, DE
Jean Rommelaere · Heidelberg, DE
Nazim El-Andaloussi · Heidelberg, DE
Georgi Hristov · Sofia, BG
Junwei Li · Beijing, CN

Key dates

Filing date	Oct 6, 2014
Grant date	Mar 14, 2017
Priority date	—
Expiry date	Nov 6, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2750/14332
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Described is a pharmaceutical composition comprising (a) a parvovirus and (b) a histone deacetylase inhibitor (HDACI) and the use of said composition for treatment of cancer, e.g., brain tumor, cervical carcinoma, or pancreatic carcinoma.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.